196 related articles for article (PubMed ID: 38369971)
1. Targeted protein degradation directly engaging lysosomes or proteasomes.
Kim J; Byun I; Kim DY; Joh H; Kim HJ; Lee MJ
Chem Soc Rev; 2024 Apr; 53(7):3253-3272. PubMed ID: 38369971
[TBL] [Abstract][Full Text] [Related]
2. Targeted Protein Degradation via Lysosomes.
Paudel RR; Lu D; Roy Chowdhury S; Monroy EY; Wang J
Biochemistry; 2023 Feb; 62(3):564-579. PubMed ID: 36130224
[TBL] [Abstract][Full Text] [Related]
3. Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins.
Lin J; Jin J; Shen Y; Zhang L; Gong G; Bian H; Chen H; Nagle DG; Wu Y; Zhang W; Luan X
Theranostics; 2021; 11(17):8337-8349. PubMed ID: 34373745
[TBL] [Abstract][Full Text] [Related]
4. Redefining the Scope of Targeted Protein Degradation: Translational Opportunities in Hijacking the Autophagy-Lysosome Pathway.
Cassidy K; Zhao H
Biochemistry; 2023 Feb; 62(3):580-587. PubMed ID: 34569233
[TBL] [Abstract][Full Text] [Related]
5. Advancement of targeted protein degradation strategies as therapeutics for undruggable disease targets.
Kannan MP; Sreeraman S; Somala CS; Kushwah RB; Mani SK; Sundaram V; Thirunavukarasou A
Future Med Chem; 2023 May; 15(10):867-883. PubMed ID: 37254917
[TBL] [Abstract][Full Text] [Related]
6. Ligandability of E3 Ligases for Targeted Protein Degradation Applications.
Belcher BP; Ward CC; Nomura DK
Biochemistry; 2023 Feb; 62(3):588-600. PubMed ID: 34473924
[TBL] [Abstract][Full Text] [Related]
7. Advancing targeted protein degradation for metabolic diseases therapy.
Zhou QQ; Xiao HT; Yang F; Wang YD; Li P; Zheng ZG
Pharmacol Res; 2023 Feb; 188():106627. PubMed ID: 36566001
[TBL] [Abstract][Full Text] [Related]
8. Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs.
Alabi SB; Crews CM
J Biol Chem; 2021; 296():100647. PubMed ID: 33839157
[TBL] [Abstract][Full Text] [Related]
9. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
Reboud-Ravaux M
Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
[TBL] [Abstract][Full Text] [Related]
10. PROTACs: An Emerging Therapeutic Modality in Precision Medicine.
Nalawansha DA; Crews CM
Cell Chem Biol; 2020 Aug; 27(8):998-1014. PubMed ID: 32795419
[TBL] [Abstract][Full Text] [Related]
11. Targeted protein degradation in cancers: Orthodox PROTACs and beyond.
Li J; Chen X; Lu A; Liang C
Innovation (Camb); 2023 May; 4(3):100413. PubMed ID: 37033156
[TBL] [Abstract][Full Text] [Related]
12. Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance.
Zhu H; Wang J; Zhang Q; Pan X; Zhang J
Pharmacol Ther; 2023 Apr; 244():108371. PubMed ID: 36871783
[TBL] [Abstract][Full Text] [Related]
13. Targeted protein degradation in drug development: Recent advances and future challenges.
Song J; Hu M; Zhou J; Xie S; Li T; Li Y
Eur J Med Chem; 2023 Dec; 261():115839. PubMed ID: 37778240
[TBL] [Abstract][Full Text] [Related]
14. Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniques.
Chen S; Cui J; Chen H; Yu B; Long S
Eur J Med Chem; 2023 Dec; 262():115911. PubMed ID: 37924709
[TBL] [Abstract][Full Text] [Related]
15. Beyond canonical PROTAC: biological targeted protein degradation (bioTPD).
Wang H; Zhou R; Xu F; Yang K; Zheng L; Zhao P; Shi G; Dai L; Xu C; Yu L; Li Z; Wang J; Wang J
Biomater Res; 2023 Jul; 27(1):72. PubMed ID: 37480049
[TBL] [Abstract][Full Text] [Related]
16. The Potential of Proteolytic Chimeras as Pharmacological Tools and Therapeutic Agents.
Coll-Martínez B; Delgado A; Crosas B
Molecules; 2020 Dec; 25(24):. PubMed ID: 33339292
[TBL] [Abstract][Full Text] [Related]
17. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
Ishida T; Ciulli A
SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
[TBL] [Abstract][Full Text] [Related]
18. Identification of KLHDC2 as an efficient proximity-induced degrader of K-RAS, STK33, β-catenin, and FoxP3.
Röth S; Kocaturk NM; Sathyamurthi PS; Carton B; Watt M; Macartney TJ; Chan KH; Isidro-Llobet A; Konopacka A; Queisser MA; Sapkota GP
Cell Chem Biol; 2023 Oct; 30(10):1261-1276.e7. PubMed ID: 37591251
[TBL] [Abstract][Full Text] [Related]
19. PROTAC antibiotics: the time is now.
Sarathy JP; Aldrich CC; Go ML; Dick T
Expert Opin Drug Discov; 2023 Apr; 18(4):363-370. PubMed ID: 37027333
[TBL] [Abstract][Full Text] [Related]
20. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
Setia N; Almuqdadi HTA; Abid M
Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]